Halozyme’s primary technology is based on its proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) that degrades hyaluronan, or HA. HA is a glycosaminoglycan, a chain of natural sugars that is a component of normal tissue, such as skin and cartilage and can also accumulate around many solid cancerous tumors.

The effects of rHuPH20 are local and transient. By degrading HA, rHuPH20 facilitates the dispersion and absorption of other drugs and fluids that are injected under the skin. In our oncology programs, we PEGylate the enzyme and administer it via intravenous injection. This is designed to allow for longer circulation in the body and delivery to tumor sites. PEGylation is the process of coupling polyethylene glycol molecules to a protein, like rHuPH20, in order to increase the protein's circulating half-life, or exposure. In animal models, the HA associated with the increased tumor pressure, decreased blood flow and restriction of the circulation of anti-cancer therapies.

HYLENEX® recombinant (hyaluronidase human injection), ENHANZE® drug delivery technology and PEGPH20 (pegvorhyaluronidase alfa) are all based on Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) that degrades hyaluronan.

Learn more about how we use the rHuPH20 enzyme to break down HA in the:


You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.